Advertisement

Cardiovascular Disease

  • Thierry Troosters
Chapter
Part of the Respiratory Medicine book series (RM)

Abstract

Many patients who suffer from chronic obstructive pulmonary disease (COPD) also suffer or even die from cardiovascular morbidity. Some authors have estimated the percentage of patients with COPD who die of cardiovascular reasons to be in the range of 12–37%. The most prevalent cardiovascular comorbidities are acute myocardial infarction, arrhythmia, chronic heart failure, peripheral vascular disease, and stroke, all of which are more prevalent in patients with COPD compared to the non-COPD population. It is no surprise that patients who suffer from COPD have increased risk of developing cardiovascular disease.

Keywords

COPD Cardiovascular disease Comorbidity Acute myocardial infarction Arrhythmia Chronic heart failure Peripheral vascular disease Stroke 

References

  1. 1.
    Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28:1245–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Engstrom G, Hedblad B, Janzon L, Valind S. Respiratory decline in smokers and ex-smokers – an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk. 2000;7:267–72.PubMedGoogle Scholar
  3. 3.
    Tockman MS, Pearson JD, Fleg JL, Metter EJ, Kao SY, Rampal KG, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med. 1995;151:390–8.PubMedGoogle Scholar
  4. 4.
    Roca B, Almagro P, Lopez F, Cabrera FJ, Montero L, Morchon D, et al. Factors associated with mortality in patients with exacerbation of chronic obstructive pulmonary disease hospitalized in General Medicine departments. Intern Emerg Med. 2011;6:47–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–8. Epub 2011 Apr 7. PMID: 21474497.Google Scholar
  6. 6.
    Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136(2):376.PubMedCrossRefGoogle Scholar
  7. 7.
    Eisner MD, Wang Y, Haight TJ, Balmes J, Hammond SK, Tager IB. Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. Ann Epidemiol. 2007;17:364–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, Newby DE, Mills NL, Macnee W. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011;66(9):769–74. Epub 2011 Apr 20.Google Scholar
  10. 10.
    Marchetti N, Ciccolella DE, Jacobs MR, Crookshank A, Gaughan JP, Kashem MA, et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011;8:60–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Spruit M, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, et al. Muscle force during an acute exacerbation in hospitalised COPD patients and its relationship with CXCL8 and IGF-1. Thorax. 2003;58:752–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary ­disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175:458–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Booth FW, Chakravarthy MV, Gordon SE, Spangenburg EE. Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. J Appl Physiol. 2002;93: 3–30.PubMedGoogle Scholar
  14. 14.
    Aoyagi Y, Park H, Kakiyama T, Park S, Yoshiuchi K, Shephard RJ. Yearlong physical activity and regional stiffness of arteries in older adults: the Nakanojo Study. Eur J Appl Physiol. 2010;109:455–64.PubMedCrossRefGoogle Scholar
  15. 15.
    Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:262–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med. 2010; 104(7):1005–111.PubMedCrossRefGoogle Scholar
  17. 17.
    MacNee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:824–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Remy-Jardin M, Remy J. Vascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:891–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Rutten FH, Moons KG, Cramer MJ, Grobbee DE, Zuithoff NP, Lammers JW, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005;331:1379.PubMedCrossRefGoogle Scholar
  21. 21.
    Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180: 513–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175:1259–65.PubMedCrossRefGoogle Scholar
  24. 24.
    Duckers JM, Shale DJ, Stockley RA, Gale NS, Evans BA, Cockcroft JR, et al. Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency. Respir Res. 2010;11:173.PubMedCrossRefGoogle Scholar
  25. 25.
    Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11:292–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Wakabayashi K, Gonzalez MA, Delhaye C, Ben-Dor I, Maluenda G, Collins SD, et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010;106:305–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Kjoller E, Kober L, Iversen K, Torp-Pedersen C. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart Fail. 2004;6:71–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail. 2007;9:942–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264:361–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;12:685–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Mascarenhas J, Lourenco P, Lopes R, Azevedo A, Bettencourt P. Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J. 2008;155:521–5.PubMedCrossRefGoogle Scholar
  32. 32.
    van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102: 192–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138:32–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Diaz H, Celli BR, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008;32:1275–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Berton DC, Barbosa PB, Takara LS, Chiappa GR, Siqueira AC, Bravo DM, et al. Bronchodilators accelerate the dynamics of muscle O2 delivery and utilisation during exercise in COPD. Thorax. 2010;65:588–93.PubMedCrossRefGoogle Scholar
  36. 36.
    Laveneziana P, Palange P, Ora J, Martolini D, O’Donnell DE. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. Eur J Appl Physiol. 2009;107:633–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Laveneziana P, Valli G, Onorati P, Paoletti P, Ferrazza AM, Palange P. Effect of heliox on heart rate kinetics and dynamic hyperinflation during high-intensity exercise in COPD. Eur J Appl Physiol. 2011;111:225–34.PubMedCrossRefGoogle Scholar
  38. 38.
    Guazzi M, Myers J, Vicenzi M, Bensimhon D, Chase P, Pinkstaff S, et al. Cardiopulmonary exercise testing characteristics in heart failure patients with and without concomitant chronic obstructive pulmonary disease. Am Heart J. 2010;160:900–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Ofir D, Laveneziana P, Webb KA, Lam YM, O’Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:622–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Janda S, Park K, Fitzgerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest. 2009;136:734–43.PubMedCrossRefGoogle Scholar
  42. 42.
    Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.PubMedCrossRefGoogle Scholar
  43. 43.
    Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med. 2011;183:50–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Reed RM, Iacono A, Defilippis A, Jones S, Eberlein M, Lechtzin N, et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD. 2011;8: 96–102.PubMedCrossRefGoogle Scholar
  45. 45.
    Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev. 2009;18:222–32.PubMedCrossRefGoogle Scholar
  46. 46.
    Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289: 1681–90.PubMedCrossRefGoogle Scholar
  47. 47.
    Can beta-blockers be used for people with COPD? Drug Ther Bull 2011;49:2–5.Google Scholar
  48. 48.
    Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566.PubMedGoogle Scholar
  49. 49.
    Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63: 301–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Vivodtzev I, Minet C, Wuyam B, Borel JC, Vottero G, Monneret D, et al. Significant improvement in arterial stiffness after endurance training in patients with COPD. Chest. 2010;137: 585–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Gale NS, Duckers JM, Enright S, Cockcroft JR, Shale DJ, Bolton CE. Does pulmonary ­rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med. 2011;11:20.PubMedCrossRefGoogle Scholar
  53. 53.
    Michaelides AP, Soulis D, Antoniades C, Antonopoulos AS, Miliou A, Ioakeimidis N, et al. Exercise duration as a determinant of vascular function and antioxidant balance in patients with coronary artery disease. Heart. 2011;97:832–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Madden KM, Lockhart C, Cuff D, Potter TF, Meneilly GS. Short-term aerobic exercise reduces arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Diabetes Care. 2009;32:1531–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation. 2004;109:220–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Richter B, Niessner A, Penka M, Grdic M, Steiner S, Strasser B, et al. Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events. Thromb Haemost. 2005;94:1306–11.PubMedGoogle Scholar
  57. 57.
    Steiner S, Niessner A, Ziegler S, Richter B, Seidinger D, Pleiner J, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis. 2005;181:305–10.PubMedCrossRefGoogle Scholar
  58. 58.
    Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, Groger M, et al. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial. Atherosclerosis. 2011;217:240–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Borjesson M, Urhausen A, Kouidi E, Dugmore D, Sharma S, Halle M, Heidbüchel H, Björnstad HH, Gielen S, Mezzani A, Corrado D, Pelliccia A, Vanhees L. Cardiovascular evaluation of middle-aged/senior individuals engaged in leisure-time sport activities: position stand from the sections of exercise physiology and sports cardiology of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2011 Jan 28. [Epub ahead of print] PMID: 21450560 [PubMed - as supplied by publisher].Google Scholar
  60. 60.
    Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:19–38.PubMedCrossRefGoogle Scholar
  61. 61.
    Troosters T, Gosselink R, Janssens W, Decramer M. Exercise training and pulmonary rehabilitation: new insights and remaining challenges. Eur Respir Rev. 2010;19:24–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Nici L, Donner C, Wouters E, ZuWallack R, Ambrosino N, Bourbeau J, et al. American thoracic society/European respiratory society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–413.PubMedCrossRefGoogle Scholar
  63. 63.
    Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:1329–35.PubMedCrossRefGoogle Scholar
  64. 64.
    McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA. 2009;301:165–74.PubMedCrossRefGoogle Scholar
  65. 65.
    Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. 2010;17:1–17.PubMedCrossRefGoogle Scholar
  66. 66.
    Graham I, Atar D, Borch-Johnsen K, Boysen G, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007;28(19):2375–414.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Pulmonary Rehabilitation, Respiratory DivisionUniversity Hospital GasthuisbergLeuvenBelgium

Personalised recommendations